Glucocorticoid Regimens for Prevention of Graves' Ophthalmopathy Progression Following Radioiodine Treatment: Systematic Review and Meta-Analysis
- 1 October 2014
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 24 (10) , 1515-1523
Abstract
Background: Glucocorticoid (GC) therapy has been shown to prevent Graves' ophthalmopathy (GO) progression following radioactive iodine (RAI) treatment. However, the optimal regimen is controversial, with studies from recent years suggesting the use of lower doses and shorter GC treatment courses. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and retrospective controlled trials comparing GC regimens versus placebo, no treatment, or other GC regimens. Results: Eight trials evaluating 850 patients fulfilled inclusion criteria. In patients with preexisting GO, standard dose prednisone (0.4–0.5 mg/kg tapered over 3 months) was very effective for prevention of GO progression (OR 0.14 [CI 0.06–0.35], p p =0.004) and no significant difference compared with standard dose (OR 1.7 [CI 0.52–5.52], p =0.47). In patients without preexisting GO, steroid prophylaxis had no beneficial effect (OR 1.87 [CI 0.81–4.3]), though there were insufficient data regarding patients with risk factors for GO development. GC prophylaxis had no impact on hyperthyroidism resolution (OR 1.05 [CI 0.69–1.58]), and GC side effects were common but mild. Conclusions: Current evidence supports a three-tier approach for prevention of GO progression following RAI. Standard dose prednisone is the best validated regimen and should be used in patients with mild to moderate GO who have high risk of progression, while low dose prednisone can be used in patients with mild GO, and in patients without preexisting GO who have risk factors and are selected for GC prophylaxis. Patients without preexisting GO and without risk factors should not be treated with GC prophylaxis.Keywords
This publication has 23 references indexed in Scilit:
- The Tale of Radioiodine and Graves' OrbitopathyThyroid®, 2010
- Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review*Clinical Endocrinology, 2008
- Radioiodine Therapy and Graves' OphthalmopathyJournal of Nuclear Medicine, 2008
- Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' OrbitopathyThyroid®, 2008
- A questionnaire survey on the management of Graves’ orbitopathy in EuropeEuropean Journal of Endocrinology, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazoleThe Journal of Clinical Endocrinology & Metabolism, 1994
- Occurrence of Ophthalmopathy after Treatment for Graves' HyperthyroidismNew England Journal of Medicine, 1992
- Use of Corticosteroids to Prevent Progression of Graves' Ophthalmopathy after Radioiodine Therapy for HyperthyroidismNew England Journal of Medicine, 1989
- RADIOIODINE AND AGGRAVATION OF GRAVES' OPHTHALMOPATHYThe Lancet, 1989